Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
About 10% of pancreatic cancer is caused by an inherited mutation in BRCA1 or BRCA2. Other genetic mutations are being studied for a link to increased risk of pancreatic cancer. Knowing if you have an inherited mutation is increasingly important for pancreatic cancer patients when making treatment decisions, because BRCA-associated cancers may respond better to certain treatments, including a treatment regimen that includes a type of chemotherapy known as platinum. Oxaliplatin is a platinum-containing drug used in some pancreatic cancer regimens.
Knowing if you have a mutation in BRCA1 or BRCA2 can affect the decision to use oxaliplatin or other platinum drug in the initial chemotherapy to treat your pancreatic cancer. Some clinical trials are using PARP inhibitors to treat pancreatic cancer patients with mutations in BRCA1/2.